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INTRODUCTION
Patients admitted to our neurology/neurosurgery ITU are frequently unconscious or sedated, and hence, have to be enterally fed. It is quite common for these patients to develop seizures post-operatively or posttrauma, or indeed they may have status epilepticus. Similarly, 3 .5% of all admissions to general ITU with primarily a non-neurological diagnosis will develop seizures 1 . For these patients, their seizures are potentially life threatening. The mortality rate for all patients who go into status epilepticus is 22% (3% for children and 26% for adults) 2 . Therefore, the administration of therapeutic doses of a recognized anticonvulsant is of paramount importance. Phenytoin is considered the agent of first choice for post-operative seizures, post-trauma seizures and for status epilepticus because therapeutic levels and response can be achieved quickly.
Phenytoin pharmacokinetics are quite problematic even in an ideal setting. It has a half-life that can vary from 13 to 46 hours and hence it takes up to 2 weeks to reach steady state 3 . Phenytoin is highly protein bound and hence levels can be severely affected by hypoalbuminaemia or renal failure 4 . Its metabolism can also be altered by hepatic impairment or indeed other drugs that are similarly metabolized, notably other anticonvulsants 5 . The additional problem which arises is that phenytoin is known to interact with most forms of enteral feed 5 , leading to erratic bioavailability and often substantial reductions in total serum phenytoin concentrations.
MATERIALS AND METHODS
On recognizing this problem, we consulted the literature, Parke-Davis Pharmaceuticals and consultants in our own unit and decided on a policy of stopping enteral feeding 2 hours before and after administration of oral or nasogastric phenytoin. This policy has now been in place for 3 years. However, review of several cases reveals that this policy has not solved the problem. Indeed, even the administration of IV phenytoin may be ineffective § .
We reviewed three cases of such patients retrospectively to gain some insight into the problem. One posttrauma (JL), one post-SAH (PW) and once with status epilepticus (SW). This review entailed documenting the phenytoin doses given (regular daily doses and boluses), the serum phenytoin levels and whether the patient was concurrently fed via a NG tube, intravenously or orally; axes labels Nasogastric (ng)/total paventeral nutrition (tpn) and oral, respectively, in the figures. These were then plotted graphically to highlight the relationship between all three factors ¶ .
RESULTS

Case study 1: (JL) Male 61 years old
JL was a pedal cyclist involved in a RTA and suffered a right subdural haematoma with midline shift and frontal lobe contusions. On admission to hospital he had one generalized tonic-clonic seizure (GTCS), and was commenced on phenytoin. He was paralysed and sedated soon after this and had no further recorded seizures. He never regained consciousness and died on day 15. JL was given only i.v. phenytoin throughout his admission. There is a noticeable decline in the serum level which was partially altered by a 50% increase in the dose (see Fig. 1 ). He did receive an initial loading of 1000 mg which would have achieved a therapeutic level (>40 mcg mol −1 L) early on. It is also noticeable that the suppression of the serum albumin is progressive throughout and this in turn lowers the total phenytoin because the albumin binding capacity has been reduced.
Case study 2: (PW) Female 49 years old
PW was transferred to W.C.N.N. with an extensive SAH on 24/6/98. She was thought to have possibly had a seizure on 4/7/98 but was not loaded with phenytoin § The therapeutic range of serum phenytoin is considered to fall between 40 and 80 µ mol −1 L. ¶ To join two points using the excel program we had to generate all points in between. until 30/7/98 (day 1) when she had a definite GTCS. She had a P.E. on 28/10/98 and died.
PW follows a similar but more prolonged pattern to the previous case. A large initial loading dose plus regular daily doses of 300 mg failed to maintain a therapeutic level and even when the daily dose was increased to 500 mg it seemed to make little impression on the serum level (see Fig. 2 ). PW died one month after day 55 and no further levels were taken. Hence, no comparisons to oral feeding can be made. However, the mirroring of phenytoin levels against serum albumin levels is quite remarkable. The total serum phenytoin rises and falls with the fluctuations in serum albumin.
Case study 3: (SW) Female 19 years old
SW was a patient with status epilepticus who was also monitored closely, and treated aggressively with several i.v. boluses and high daily doses (see Fig. 3 ). This regimen was indeed successful at maintaining the required level but as solid food was commenced the phenytoin levels climbed into the toxic range and she was symptomatic. SW also had low serum albumin levels until dietician intervention at around day seven. As her nutrition improved, it had the gradual effect of helping to raise her albumin. This may have contributed to the rise in total serum phenytoin.
DISCUSSION
On studying these examples a consistent pattern can be seen to be emerging. After admission and loading with phenytoin the initial level drops dramatically within days. This coincides with commencement of concurrent nasogastric feeding and observably low serum albumin levels.
Significantly increasing the daily dose of phenytoin, whether i.v. or oral, has little impact on levels. However, vigilant monitoring and administration of appropriate boluses produces total phenytoin levels within the target range. It should be borne in mind that steady state for serum phenytoin can take up to 2 weeks to achieve but with these patients we are often not afforded the luxury of this time.
Whether or not seizures are suppressed by levels within the target range, another problem occurs once solid feeding has been recommenced because phenytoin toxicity on the same regular dose can occur inconspicuously. This is a particular problem once the patient leaves the ITU setting.
Phenytoin is usually about 90% protein bound 6 . However, it may be the case that due to the dynamic haematological conditions, the patient may have higher levels of 'free' phenytoin even though their 'total' phenytoin level is considered subtherapeutic. It may be more appropriate to monitor 'free' phenytoin levels. This is a difficult area to study owing to the limitations placed upon investigators by the nature of the subjects being examined. They are acutely ill, may be suffering from multiple complicating factors (including neurological ones), and hence entering them into a controlled clinical trial would be ethically questionable. Therefore, the reporting of this problem is anecdotal. These three cases have been selected because they are good examples of a problem which is seen consistently within our unit.
There are conflicting views 7, 8 regarding the interaction between phenytoin and NG feeding, some in support of this interaction 7 , and some which refute it as a myth 8 . Assuming an interaction exists, there are two possible explanations for this interaction.
Firstly, it could be due to poor absorption of the phenytoin from the gastro-intestinal tract (GIT). Randall and Tett 9 suggest a physicochemical reaction producing a nonabsorbable complex between the phenytoin and the enteral feed which may be hampering absorption, but this is refuted by Krueger et al. 10 . They suggest it may have more to do with the en-teral feed having an adverse effect on the motility and absorptive capabilities of the GIT in respect to the phenytoin but further research is necessary. Secondly suppression of phenytoin levels could be the result of increased metabolic clearance due to changes in protein binding, induction of hepatic metabolism or stress related transient increases in hepatic function 9 or combinations of these factors 11 .
CONCLUSIONS
The ITU patient with seizures who is receiving phenytoin and being enterally fed will fall into one of the following scenarios:-(1) They have low serum phenytoin levels but no further seizures. They should be observed closely monitoring both phenytoin and serum albumin.
(2) They have low phenytoin levels and poorly controlled seizures. Levels should be measured daily and bolus (es) given to maintain target levels.
(3) The patient is adequately controlled with phenytoin levels in the target range.
Irrespective of which category they fall into, when the patient is changed back from enteral to normal food they should again be monitored closely for some time for their phenytoin levels can easily become toxic. They are especially at risk once they have left the ITU setting.
Whilst the research is obviously needed in this area, phenytoin remains, pharmacokinetically, a dynamic drug which suffers a complexity of interactions with other drugs and feeds 5 . Clinicians should be monitoring the target levels not the dose being administered nor the seizure free status of the patient as the sole methods of monitoring phenytoin efficacy and toxicity.
